센테사 파마슈티컬스 PLC ADR(CNTA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $40.50 (+0.80%), 시가총액 $6.13B, 52주 최저~최고 $11.86 ~ $39.86.
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program tech
센테사 파마슈티컬스 PLC ADR의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
센테사 파마슈티컬스 PLC ADR의 현재 주가는 $40.50 (+0.80%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
센테사 파마슈티컬스 PLC ADR의 시가총액은 약 $6.13B입니다.
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops